PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19813266-0 2010 Genistein induces receptor and mitochondrial pathways and increases apoptosis during BCL-2 knockdown in human malignant neuroblastoma SK-N-DZ cells. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 85-90 19813266-3 2010 The present study sought to elucidate the molecular mechanism of genistein-induced apoptosis and also to examine the effect of genistein in increasing apoptosis during Bcl-2 knockdown in human malignant neuroblastoma SK-N-DZ cells. Genistein 127-136 BCL2 apoptosis regulator Homo sapiens 168-173 19813266-12 2010 Our study demonstrates that Bcl-2 knockdown during genistein treatment effectively induced apoptosis in neuroblastoma cells. Genistein 51-60 BCL2 apoptosis regulator Homo sapiens 28-33 20067268-7 2010 In addition, genistein increased nucleosomal DNA fragmentation, increased the expression levels of Bax and c-Myc, and decreased the expression levels of Bcl-2 and Bcl-xL in TNF-alpha-induced HASMCs. Genistein 13-22 BCL2 apoptosis regulator Homo sapiens 153-158 19732843-7 2009 Moreover, genistein enhances the phosphorylation and activation of p53, while decreases the ratio of Bcl-2/Bax and Bcl-xL/Bax and the level of phosphorylated Akt, which result in cells undergoing apoptosis. Genistein 10-19 BCL2 apoptosis regulator Homo sapiens 101-106 19994890-11 2010 Additionally, treatment with genistein (6) changed the ratio of expression levels of pro- and anti-apoptotic Bcl-2 family members and subsequently induced the activation of caspase-9 and caspase-3, which was followed by cleavage of poly(ADP-ribose) polymerase (PARP). Genistein 29-38 BCL2 apoptosis regulator Homo sapiens 109-114 19932626-0 2010 Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells. Genistein 88-97 BCL2 apoptosis regulator Homo sapiens 19-24 19932626-2 2010 Since genistein is known to suppress Bcl-2 expression, we predicted that photodynamic therapy with hypericin might benefit from mutual therapeutic combination. Genistein 6-15 BCL2 apoptosis regulator Homo sapiens 37-42 18470428-4 2008 Treated with 220 micromol/L genistein for 3 days, the expression level of bax protein was 3.43 folds of the control group (P<0.01),but the expression level of bcl-2 and survivin proteins was respectively 85%(P<0.05) and 35%(P<0.01) of the control group. Genistein 28-37 BCL2 apoptosis regulator Homo sapiens 162-167 19393315-6 2009 Genistein and daidzein upregulated the estrogen receptor ERbeta and increased Bcl-2 expression. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 78-83 19393315-7 2009 Silencing of Bcl-2 with siRNA abolished the protection of genistein. Genistein 58-67 BCL2 apoptosis regulator Homo sapiens 13-18 19082897-4 2009 The anti-apoptotic effect of genistein was associated with an enhanced expression of Bcl-2 protein and its promoter activity. Genistein 29-38 BCL2 apoptosis regulator Homo sapiens 85-90 18357397-12 2008 The ectopic expression of the anti-apoptotic BCL-2 protein attenuated the cytotoxic effects of genistein. Genistein 95-104 BCL2 apoptosis regulator Homo sapiens 45-50 18761399-6 2008 Genistein down-regulates Bcl-2 and up-regulates Bax. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 25-30 18761399-7 2008 NF-kappaB binding sites are present in the promoter of Bcl-2, suggesting that genistein might inhibit the expression of Bcl-2 through down-regulation of NF-kappaB. Genistein 78-87 BCL2 apoptosis regulator Homo sapiens 55-60 18761399-7 2008 NF-kappaB binding sites are present in the promoter of Bcl-2, suggesting that genistein might inhibit the expression of Bcl-2 through down-regulation of NF-kappaB. Genistein 78-87 BCL2 apoptosis regulator Homo sapiens 120-125 18470428-5 2008 CONCLUSION: The cell apoptosis induced by genistein in human salivary adenoid cystic carcinoma cell line SACC-83 may be associated with the upregulation of bax protein expression,and the downregulations of bcl-2 and survivin proteins expression. Genistein 42-51 BCL2 apoptosis regulator Homo sapiens 206-211 15659824-3 2004 This study examined genistein-induced apoptosis through the regulation of bcl-2 and bax expression in the presence of estrogen. Genistein 20-29 BCL2 apoptosis regulator Homo sapiens 74-79 17786319-6 2007 We found that genistein induces enhanced cytochrome c release and mitochondrial membrane depolarization in MCF-7/Bcl-2 cells, as compared to control. Genistein 14-23 BCL2 apoptosis regulator Homo sapiens 113-118 17786319-8 2007 Cell cycle analysis indicated that genistein induces G0/G1 arrest in MCF-7/PV cells but increases in G2/M arrest in MCF-7/Bcl-2 cells. Genistein 35-44 BCL2 apoptosis regulator Homo sapiens 122-127 15907805-5 2005 Jurkat/TP cells showed weak phosphorylation of Bcl-2, and kinase inhibitors staurosporine and genistein attenuated not only MIA-induced Bcl-2 phosphorylation but also cytotoxicity of MIA in Jurkat/CV, but not in Jurkat/TP. Genistein 94-103 BCL2 apoptosis regulator Homo sapiens 136-141 18388472-8 2008 In general, apoptosis signaling cascades were activated by the following events: release of cytochrome c, upregulation of Bax, downregulation of Bcl-2, and activation of caspase-3 and -8 in the treatment of genistein and irradiation. Genistein 207-216 BCL2 apoptosis regulator Homo sapiens 145-150 17786319-2 2007 Genistein-induced apoptosis involves Bcl-2 downregulation. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 37-42 17786319-5 2007 Our results demonstrate that overexpression of Bcl-2 rendered MCF-7 cells more sensitive, rather than resistant, to genistein. Genistein 116-125 BCL2 apoptosis regulator Homo sapiens 47-52 16329599-9 2005 CONCLUSION: Our results demonstrated that genistein inhibited the viability of human colon cancer HT-29 cell via induction of apoptosis mainly through regulation of PCNA and Bax/Bcl-2 expression. Genistein 42-51 BCL2 apoptosis regulator Homo sapiens 178-183 15188515-8 2004 Immunohistochemical staining showed that after the treatment of primary gastric cancer cells with genistein for 24 to 96 h, the positivity rates of Bcl-2 proteins were apparently reduced with time and the positivity rates of Bax proteins were apparently increased with time. Genistein 98-107 BCL2 apoptosis regulator Homo sapiens 148-153 15288519-8 2004 Moreover, genistein was able to prevent the down-regulation of the anti-apoptotic protein bcl-2 that was caused by t-BuOOH treatment. Genistein 10-19 BCL2 apoptosis regulator Homo sapiens 90-95 15288519-9 2004 These results indicate that genistein may have neuroprotective effect in cortical cells, which may be mediated by its regulation of the anti-apoptotic protein bcl-2. Genistein 28-37 BCL2 apoptosis regulator Homo sapiens 159-164 15488634-6 2004 Our results demonstrated that genistein inhibited the viability of human colon cancer HT-29 cell via induction of apoptosis mainly through regulation of p21WAF1 and Bax/Bcl-2 expression. Genistein 30-39 BCL2 apoptosis regulator Homo sapiens 169-174 15135300-8 2004 Genistein reduced Bcl-2 phosphorylation triggered by paclitaxel and vincristine without changing Bax protein expression. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 18-23 15135300-11 2004 In conclusion, genistein inversely affected tubulin-binding agent-induced apoptosis via down-regulation of cyclin B1/CDC2 kinase expression resulting in reduced Bcl-2 phosphorylation. Genistein 15-24 BCL2 apoptosis regulator Homo sapiens 161-166 15188515-9 2004 After exposed to genistein at 20 micromol/L for 24, 48, 72 and 96 respectively, the density of bcl-2 mRNA decreased progressively and the density of bax mRNA increased progressively with elongation of time. Genistein 17-26 BCL2 apoptosis regulator Homo sapiens 95-100 12950722-10 2003 The combined treatment with genistein and cisplatin significantly reduced bcl-2 and bcl-xL protein and increased Apaf-1 protein expression. Genistein 28-37 BCL2 apoptosis regulator Homo sapiens 74-79 14707277-16 2003 At 30 micro M, genistein inhibited the growth significantly, induced G(2)-M arrest, increased Bax:Bcl-2 ratio, decreased NF-kappaB DNA binding, and induced apoptosis. Genistein 15-24 BCL2 apoptosis regulator Homo sapiens 98-103 12948406-18 2003 The onset of apoptosis in ovarian carcinoma cell is related to the up-regulation of bax and down-regulation of bcl-2 in mRNA and protein level induced by Genistein. Genistein 154-163 BCL2 apoptosis regulator Homo sapiens 111-116 11767000-3 2001 The PTK inhibitor genistein (GEN) and PKC inhibitor staurosporine (STP) down-regulated Mcl-1 and Bcl-2 expression, and induced growth inhibition by blocking at the G2/M phase of cell cycle, followed by apoptosis, leading to chromatin condensation and DNA fragmentation. Genistein 18-27 BCL2 apoptosis regulator Homo sapiens 97-102 11751518-5 2001 Oncol., 16: 333-338, 2000) that genistein induces cell cycle arrest and apoptosis by up-regulating p21(WAF1) and Bax, and down-regulating cyclin B1 and Bcl-2 in a head and neck cancer cell line. Genistein 32-41 BCL2 apoptosis regulator Homo sapiens 152-157 12239620-12 2002 The induction of apoptosis by GEN was associated with a 52.8% decrease (p=0.001) in the immunoreactivity to antiapoptotic Bcl-2 and with a 195.9% (p=0.001) increase in the immunoreactivity to proapoptotic Bax. Genistein 30-33 BCL2 apoptosis regulator Homo sapiens 122-127 12239620-13 2002 Thus, preventive efficacy of GEN in HER-2/neu+/ER- 184-B5/HER cells may be due to its ability to down-regulate HER-2/neu mediated signal transduction, increase the expression of the cyclin dependent kinase inhibitor p16INK4, and induce Bcl-2 dependent apoptosis. Genistein 29-32 BCL2 apoptosis regulator Homo sapiens 236-241 11767000-3 2001 The PTK inhibitor genistein (GEN) and PKC inhibitor staurosporine (STP) down-regulated Mcl-1 and Bcl-2 expression, and induced growth inhibition by blocking at the G2/M phase of cell cycle, followed by apoptosis, leading to chromatin condensation and DNA fragmentation. Genistein 29-32 BCL2 apoptosis regulator Homo sapiens 97-102 33745261-0 2020 Genistein Induces Bcl-2 Expression in Human Dermal Microvascular Endothelial Cells: a Short Report. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 18-23 11316564-6 2001 In terms of changes in expression of p53-related proteins, increase in expression of Bax and decrease in that of Bcl-2 were observed in TE-2 but not in TE-1, suggesting that the main mode of cell death induced by genistein in a cell line with wild type p53 differed from that with mutant p53. Genistein 213-222 BCL2 apoptosis regulator Homo sapiens 113-118 11074606-4 2000 Physiologic concentrations of genistein (< or = 20 microM) decreased LNCaP viable cell number in a dose-dependent manner, induced a G(1) cell-cycle block, decreased prostate-specific antigen mRNA expression, and increased p27(KIP1) and p21(WAF1) (mRNA and protein) but had no effect on apoptosis or the mRNA expression of the apoptosis- and cell-cycle-related markers bcl-2, bax, Rb, and proliferating cell nuclear antigen. Genistein 30-39 BCL2 apoptosis regulator Homo sapiens 371-376 33347704-10 2021 The results from western blotting demonstrated that the treatment of GEN combined with Asp showed a higher increase in the levels of Bax and Bak (pro-apoptotic proteins) and an active form of caspase-3 and a higher decrease in Bcl-2 (anti-apoptotic protein) than that of GEN or Asp treatment alone. Genistein 69-72 BCL2 apoptosis regulator Homo sapiens 227-232 31958764-11 2020 Interestingly, down-regulated expressions of endogenous miR-95, SGK1, Bcl-2, Erk1 were observed after genistein treatments in a dose-dependent way. Genistein 102-111 BCL2 apoptosis regulator Homo sapiens 70-75 11110847-8 2000 Therefore, the mechanism of genistein-induced apoptosis at this concentration might rely largely on the stress pathway rather than the pathway mediated by the Bcl-2 family of proteins. Genistein 28-37 BCL2 apoptosis regulator Homo sapiens 159-164 10023317-0 1998 Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 22-27 9596995-4 1998 Using human IL-3-dependent TF-1 cells, we have found that the tyrosine kinase inhibitor genistein blocks both the IL-3 suppression of apoptosis and the expression of the cell survival gene bcl-2. Genistein 88-97 BCL2 apoptosis regulator Homo sapiens 189-194 9596995-7 1998 Significantly, genistein inhibited the IL-3 induction of both bcl-2 and c-myc gene. Genistein 15-24 BCL2 apoptosis regulator Homo sapiens 62-67 21590211-5 1997 Incubating the cells with genistein, a protein tyrosine kinase inhibitor, inhibited the taxol-induced modified Bcl-2 expression and apoptosis. Genistein 26-35 BCL2 apoptosis regulator Homo sapiens 111-116 33745261-3 2020 In the present study we aimed to answer the question whether genistein increases expression of Bcl-2, a potent anti-apoptotic protein, in human dermal microvascular endothelial cells (HMVEC-d) as well. Genistein 61-70 BCL2 apoptosis regulator Homo sapiens 95-100 33745261-4 2020 Our results showed that administration of genistein induces Bcl-2 expression in a concentration-dependent manner. Genistein 42-51 BCL2 apoptosis regulator Homo sapiens 60-65 33745261-5 2020 Cell co-treatment with genistein and anti-ER compounds (MPP, PHTPP, ICI, G-15) diminished the observed positive effect of genistein on Bcl-2 expression. Genistein 23-32 BCL2 apoptosis regulator Homo sapiens 135-140 33745261-5 2020 Cell co-treatment with genistein and anti-ER compounds (MPP, PHTPP, ICI, G-15) diminished the observed positive effect of genistein on Bcl-2 expression. Genistein 122-131 BCL2 apoptosis regulator Homo sapiens 135-140 33745261-7 2020 In conclusion, genistein increases Bcl-2 expression in HMVEC-d, contributing to its protective effect on the skin flap viability. Genistein 15-24 BCL2 apoptosis regulator Homo sapiens 35-40 31538075-8 2019 Bcl2 expression was reduced by 69% in the cisplatin+genistein group compared to that in the cisplatin group. Genistein 52-61 BCL2 apoptosis regulator Homo sapiens 0-4 31360194-15 2019 Genistein also triggered apoptosis which was associated with upregulation of cytosolic cytochrome c, Bax, cleaved caspase 3 and 9 expression and downregulation of Bcl-2 expression in HepG2 cells. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 163-168 31438633-6 2019 In addition, genistein increased the cytosolic release of cytochrome c by increasing the Bax/Bcl-2 ratio and destroying mitochondria integrity. Genistein 13-22 BCL2 apoptosis regulator Homo sapiens 93-98 30618158-8 2019 Western blotting assay demonstrated that genistein increased ER stress-associated protein expression such as IRE-1alpha, Calpain 1, GRP78, GADD153, caspase-7, caspase-4, and ATF-6alpha at 20-50 muM treatment and increased apoptosis associated protein expression such as pro-apoptotic protein Bax, PARP-cleavage, caspase-9, and -3, but decreased anti-apoptotic protein such as Bcl-2 and Bid in HL-60 cells. Genistein 41-50 BCL2 apoptosis regulator Homo sapiens 376-381 27121018-10 2016 Treatment of the HEp-2 cells with genistein and TSA led to a significant reduction in the phosphorylation of Akt and activation of its downstream target, and resulted in peroxisome proliferator-activated receptor-gamma cleavage, increased expression of B cell lymphoma-2 (Bcl-2)-associated X protein and reduced the expression of Bcl-2. Genistein 34-43 BCL2 apoptosis regulator Homo sapiens 253-270 30450837-5 2019 Abeta25-35 -induced changes in Ca2+ and B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X (Bax) protein and gene levels in cells were also reversed by genistein. Genistein 150-159 BCL2 apoptosis regulator Homo sapiens 40-57 30450837-5 2019 Abeta25-35 -induced changes in Ca2+ and B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X (Bax) protein and gene levels in cells were also reversed by genistein. Genistein 150-159 BCL2 apoptosis regulator Homo sapiens 59-64 30106049-6 2018 Western blot assays showed that BCL-2 and Beclin 1 levels were markedly higher in the genistein group than in the rotenone group. Genistein 86-95 BCL2 apoptosis regulator Homo sapiens 32-37 30003731-8 2018 RT-qPCR and Western blot showed that the expression levels of anti-apoptotic factor Bcl-2 in A549 cells were significantly decreased at both mRNA and protein levels at 48 hrs after treatment with GEN, but the levels of pro-apoptotic Bax were significantly increased at both mRNA and protein levels. Genistein 196-199 BCL2 apoptosis regulator Homo sapiens 84-89 29202800-7 2017 Moreover, genistein can inhibit the expression of notch-1, p-NF-kappaB and NF-kappaB, while promote the expression of Bax/Bcl-2 and caspase-3 in HT-29 cells. Genistein 10-19 BCL2 apoptosis regulator Homo sapiens 122-127 27121018-10 2016 Treatment of the HEp-2 cells with genistein and TSA led to a significant reduction in the phosphorylation of Akt and activation of its downstream target, and resulted in peroxisome proliferator-activated receptor-gamma cleavage, increased expression of B cell lymphoma-2 (Bcl-2)-associated X protein and reduced the expression of Bcl-2. Genistein 34-43 BCL2 apoptosis regulator Homo sapiens 272-277 27121018-10 2016 Treatment of the HEp-2 cells with genistein and TSA led to a significant reduction in the phosphorylation of Akt and activation of its downstream target, and resulted in peroxisome proliferator-activated receptor-gamma cleavage, increased expression of B cell lymphoma-2 (Bcl-2)-associated X protein and reduced the expression of Bcl-2. Genistein 34-43 BCL2 apoptosis regulator Homo sapiens 330-335 26841510-4 2015 The decreased Bax mRNA expression and increased Bcl-2 mRNA expression after incubation .of the cells with genistein also demonstrate the cytoprotective, anti-apoptotic effect of genistein. Genistein 106-115 BCL2 apoptosis regulator Homo sapiens 48-53 22493348-0 2012 Physiological concentrations of genistein and 17beta-estradiol inhibit MDA-MB-231 breast cancer cell growth by increasing BAX/BCL-2 and reducing pERK1/2. Genistein 32-41 BCL2 apoptosis regulator Homo sapiens 126-131 25128065-6 2014 In the present study, we demonstrated that genistein could induce apoptosis in human colon cancer LoVo and HT-29 cells through inhibiting NF-kappaB pathway, as well as downregulation of Bcl-2 and upregulation of Bax, thus providing basis for clinical application of genistein in colon cancer cases. Genistein 43-52 BCL2 apoptosis regulator Homo sapiens 186-191 22493348-4 2012 High concentrations of genistein (100 muM) both in the presence and absence of 17beta-estradiol also increased apoptosis; however, these changes were not correlated with the BAX/BCL-2 ratio or with phosphorylation of ERK1/2. Genistein 23-32 BCL2 apoptosis regulator Homo sapiens 178-183 26064333-5 2015 RESULTS: Combined treatment with ATRA and Genistein was able to reduce the expressions of Bcl-2, MUC1 and ICAM-1 and exerted synergistic effects to inhibit the invasion of A549 cells. Genistein 42-51 BCL2 apoptosis regulator Homo sapiens 90-95 26064333-6 2015 CONCLUSION: ATRA and Genistein may synergistically inhibit MUC1 and ICAM-1 expressions and affect the expressions of cell cycle related proteins (CDK4, Rb and p-ERK1/2) and apoptosis related proteins (Bax and Bcl-2), inhibit the metastatic potential of lung cancer A549 cells. Genistein 21-30 BCL2 apoptosis regulator Homo sapiens 209-214 25675448-8 2015 Furthermore, genistein induced the inactivation of IGF-1R and p-Akt and downregulated the Bcl-2/Bax protein ratio. Genistein 13-22 BCL2 apoptosis regulator Homo sapiens 90-95 25675448-9 2015 These results suggest that genistein inhibited cell proliferation by inactivating the IGF-1R-PI3 K/Akt pathway and decreasing the Bcl-2/Bax mRNA and protein expressions. Genistein 27-36 BCL2 apoptosis regulator Homo sapiens 130-135 24573886-8 2014 Genistein increased in three times proapoptotic BAX/Bcl-2 ratio and promoted a parallel downregulation of 20 times of antiapoptotic survivin. Genistein 0-9 BCL2 apoptosis regulator Homo sapiens 52-57 22493348-3 2012 RESULTS: Compared to the control, 1 muM genistein plus 1 nM 17beta-estradiol significantly increased apoptosis, and the BAX/BCL-2 ratio, with a concomitant decrease in ERK1/2 phosphorylation. Genistein 40-49 BCL2 apoptosis regulator Homo sapiens 124-129 20824697-4 2011 Drug resistance of PC is allegedly linked with both constitutive and OxP-induced activation of NF-kappaB, and we found that inactivation of (nuclear factor kappa B) NF-kappaB by genistein before treatment of cells with OxP was required for cell killing, which was consistent with the downregulation of NF-kappaB and its downstream antiapoptotic genes (Bcl-2, XIAPs and survivin). Genistein 178-187 BCL2 apoptosis regulator Homo sapiens 352-357 22227334-9 2012 Furthermore, genistein pretreatment restored the 6-OHDA-induced up-regulation of Bax and down-regulation of Bcl-2 mRNA and protein expression. Genistein 13-22 BCL2 apoptosis regulator Homo sapiens 108-113 19800779-7 2010 While genistein, resveratrol and glycitein all increased apoptosis and reduced the Bcl-2/Bax ratio, resveratrol reduced this ratio more than either genistein or glycitein. Genistein 6-15 BCL2 apoptosis regulator Homo sapiens 83-88 21078540-5 2011 The mechanism is at least partially due to the suppressive effect of genistein both on the proper and ATO-induced Akt activation, and on the activity of NF-kappaB, and the latter correlated with the suppression of NF-kappaB regulated gene products, including cyclin D1, Bcl-xL, Bcl-2, c-myc, COX-2, and VEGF. Genistein 69-78 BCL2 apoptosis regulator Homo sapiens 278-283 19800779-9 2010 On knockdown analysis, genistein, resveratrol and glycitein all reduced the Bcl-2/Bax ratio in the presence of apoptosis-inducing stimuli, and estrogen receptor (ER) alpha silencing had no effect on these reductions. Genistein 23-32 BCL2 apoptosis regulator Homo sapiens 76-81